Alberta-based vertically integrated cannabis operator CanadaBis (CVE:CANB) announced the results from their Q3 2024 for the company and its subsidiaries Stigma Pharmaceuticals Inc., Stigma Grow, Stigma Roots, Indicative Collection and Goldstream Cannabis Inc. Despite showing a decrease of 26% YoY for Q3, the company highlighted the fact that it is its tenth consecutive quarter generating revenue. The positive results come amid a challenging economy for Cannabis in Canada, which pushed the company to seek increased operational efficiency. “Canadabis Capital’s performance in Q3 2024 was robust, driven by our strategic investments and continuous efforts to optimize our operational efficiencies,” said CEO Travis ...